Skip to main content
Premium Trial:

Request an Annual Quote

GPC Biotech and Boehringer Ingelheim Collaborate on Drug Target Project

NEW YORK, Jan 9 – GPC Biotech has signed on to a proteomics and genomics deal with Boehringer Ingelheim pharmaceuticals, in which GPC will identify targets and pathways associated with human papillomavirus, GPC announced Tuesday.

In this project, GPC Biotech is using OliCode molecular cloning technology, PathCode yeast two-hybrid protein-protein interaction identification technology, and its bioinformatics applications.

Based on these targets, Boehringer Ingelheim hopes to develop new treatments and preventative therapies for HPV-related illnesses.

Boehringer Ingelheim is paying GPC Biotech license fees, milestone payments for clinical development, and royalties on sales of any products it develops using GPC Biotech’s targets.

Boehringer Ingelheim will also provide research funding for research. GPC estimated that total payments from Boehringer Ingelheim could add up to $30 million.

This deal follows an earlier collaboration, in which GPC Biotech defined gene expression profiles for Boehringer Ingleheim using its ExpressCode technology and provided information about target function.

GPC has also formed similar partnerships with Aventis, Bayer, Du Pont, Altana, Cell Genesys, Maxim Pharmaceuticals, Evotec Biosystems, Morphosys, and Karo Bio.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.